Two obesity drugs do the exact opposite thing to the same receptor. Both make you lose weight. That contradiction has bugged metabolism researchers for years, and a mouse study out of Cambridge finally explains it: the two drug classes aren’t fighting over the same target at all. They’re working in different parts of the brain.
The study, published in Nature Metabolism, comes from the Institute of Metabolic Science at the University of Cambridge. Activating the receptor in the brainstem cut appetite. Blocking that same receptor in the hypothalamus dropped weight too, through a completely separate mechanism.
The receptor that works both ways
Some background on why this was confusing in the first place. A newer class of weight loss drugs works by hitting receptors tied to appetite, reducing food intake, driving weight loss and helping regulate blood sugar.
Wegovy and Ozempic, the two names everyone knows, activate the glucagon-like peptide 1 receptor, or GLP-1R. Straightforward enough.
Then there’s a second target: the glucose-dependent insulinotropic polypeptide receptor, GIPR. Mounjaro and Zepbound activate it. MariTide blocks it. Opposite pharmacology, same receptor, and both approaches can promote weight loss.
You can see why that’s a problem for anyone trying to design the next drug. If you don’t know why something works, you’re guessing at how to make it work better.
How they pinned down the brain regions
The Cambridge team went at it with genetically engineered mice. One group had GIPR removed from the brainstem, the region at the base of the brain just above the spinal cord that handles appetite and nausea. A second group had it removed from the hypothalamus, which regulates hunger and body weight. A third group was normal mice, as controls.
Then they dosed the animals with different combinations: a GIPR agonist to activate the receptor, a GIPR antagonist to block it, and a GLP-1 drug. They tracked food consumption, body weight, fat mass, blood sugar control and brain activity.
Comparing what happened across the three groups told them where each drug was doing its work. Knock out the receptor in one region, watch which treatment stops working, and you’ve found your address.
Agonists turned out to run through the brainstem. Switch GIPR on there and appetite drops, body weight follows.
The brake on your sense of fullness
Antagonists took a different road entirely. Blocking GIPR drove weight loss through the hypothalamus, not the brainstem.
And here’s the part worth sitting with. In the hypothalamus, GIPR seems to act as a kind of ‘brake’ on how strongly the brainstem reacts to signals that the body is full. Block the receptor, release the brake, and those fullness signals hit harder.
So one drug class quiets appetite directly. The other stops your brain from muffling the signal that you’ve had enough. Same receptor, two unrelated jobs, depending on the neighborhood.
The team also found signs that blocking GIPR could boost drugs aimed at the amylin receptor, which are still emerging. That hints GIPR antagonists might end up strengthening several different classes of obesity treatment rather than just one.
What this means for MariTide and combination drugs
MariTide is the obvious beneficiary here. It’s in phase 3 clinical trials and pairs GIPR antagonism with GLP-1 receptor agonism, and the Cambridge results help explain why that pairing does anything at all.
Map out the separate pathways and you can start designing combinations on purpose instead of by trial and error.
Dr. Jo Lewis, the study’s first author from the Institute of Metabolic Science at the University of Cambridge, said: “Understanding which brain circuits respond to these medications – and how they do so – could help us design better drugs that produce more weight loss with fewer side effects, and which might work in combination with other obesity medicines to even greater effect.”
Lewis said: “Our work also strengthens the idea that the brain is central to obesity treatment. Obesity drugs are not acting simply on the gut or pancreas. Instead, they have important effects on specific, identifiable brain circuits that regulate appetite and food intake.”
The caveat that matters
This is a mouse study. Nobody has shown these circuits behave identically in people, and the findings may help scientists build better treatments rather than having already done so.
Still, the scale of the problem explains the urgency. More than a billion people worldwide are living with obesity, which raises the risk of type 2 diabetes, cardiovascular disease and cancer. Weight loss can cut some of that risk, but getting there on diet and exercise alone is hard.
The research was funded by the Medical Research Council and Wellcome.
If you’re tracking this field, the thing to watch isn’t the next single-target drug. It’s whether anyone can stack a brainstem-acting agonist and a hypothalamus-acting antagonist without the side effects piling up too.
